The results are shown inFig

The results are shown inFig.2. asymmetric dimer occurs in a specific sequence and depends on the kinase activity of the EGF receptor. The EGF receptor is usually a member of the ErbB family of receptor tyrosine kinases that also includes ErbB2, ErbB3, and ErbB4 (1,2). All ErbB receptors contain an extracellular ligand-binding domain name, a single pass transmembrane domain name, an intracellular tyrosine kinase, and a C-terminal tail (3). The EGF receptor, ErbB3, and ErbB4 are activated through the binding of a family of homologous ligands (4). Unique among the ErbB receptors, ErbB2 has no known ligand (5,6). Binding of an ErbB ligand to its receptor induces dimerization of the receptor through interaction of the extracellular domains. Essentially all combinations of ErbB receptors are possible. However, the ligandless ErbB2 appears to be the preferred heterodimerization partner among ErbB receptors (7,8). Ligand-induced dimerization of the extracellular domains leads to the activation of the intracellular tyrosine kinase through the formation of an asymmetric kinase dimer (911). In the asymmetric dimer, the C lobe of the activator kinase interacts with the N lobe of the receiver kinase in a manner similar to that in which cyclin A interacts with cyclin-dependent kinase (12). This interaction leads to the activation of the receiver kinase, which then phosphorylates the C-terminal tail of the activator kinase. Although a substantial body of evidence supports this model for EGF receptor kinase activation (911,13), it is not clear how the binding of ligand to the extracellular domain directs the assembly of the intracellular asymmetric kinase dimer. In particular, if ligand binds to one subunit in an ErbB dimer, which kinase domain adopts the activator and which adopts the receiver position in the asymmetric dimer, or is the choice made randomly? Once formed, does the asymmetric kinase dimer readily shift from one configuration to the reciprocal one, activating each kinase in turn, or is this a controlled process? We have previously used luciferase fragment complementation imaging to monitor the dimerization of and Solifenacin succinate conformational dynamics in the EGF receptor in real time in live cells (14,15). Stimulation of full-length receptors with EGF leads to a rapid decrease in luciferase activity followed by a slower recovery back to baseline levels. The results suggest that luciferase complementation can take place in EGF receptor predimers (1620). Upon addition of EGF, a conformational change occurs that initially separates the luciferase fragments but subsequently they are brought back into proximity. These conformational dynamics are strictly dependent on kinase activation. In the kinase-dead EGF receptor, where dimerization occurs but no phosphorylation Rabbit polyclonal to ZNF624.Zinc-finger proteins contain DNA-binding domains and have a wide variety of functions, mostof which encompass some form of transcriptional activation or repression. The majority ofzinc-finger proteins contain a Krppel-type DNA binding domain and a KRAB domain, which isthought to interact with KAP1, thereby recruiting histone modifying proteins. Zinc finger protein624 (ZNF624) is a 739 amino acid member of the Krppel C2H2-type zinc-finger protein family.Localized to the nucleus, ZNF624 contains 21 C2H2-type zinc fingers through which it is thought tobe involved in DNA-binding and transcriptional regulation takes place, only a monotonic rise in luciferase activity is observed (14). Thus, the pattern of luciferase complementation is distinctly different for wild-type and kinase-dead receptors. In the work reported here, we use luciferase fragment complementation imaging to monitor the ability of the EGF receptor to interact with and activate the ligandless ErbB2. We find that EGF induces the same conformational dynamics in the kinase-active EGF receptor (EGFR)/ErbB2 heterodimer as it does in the kinase-active EGF receptor homodimer. Similarly, EGF elicited the characteristic monotonic Solifenacin succinate rise in luciferase activity in the kinase-dead version of the EGF receptor/ErbB2 heterodimer. Interestingly, in half-dead heterodimers containing one wild-type and one kinase-dead receptor, the pattern of luciferase activity was determined by the activity status of the kinase domain of the ligand-binding EGF receptor subunit. Assays of kinase and signaling activities in the half-dead pairs were consistent with the results of the luciferase assays. The data support a model in which Solifenacin succinate ligand binding directs the EGF receptor to adopt the receiver position in the asymmetric dimer and to phosphorylate ErbB2. In the absence of this phosphorylation event, the ErbB2 kinase domain is never activated. These observations provide key mechanistic insight into the activation and functioning of the EGF receptor/ErbB2 asymmetric kinase dimer. == Results == == Dimerization of the EGF Receptor and ErbB2. == Firefly luciferase can be split into an N-terminal fragment and a C-terminal fragment, neither one of which exhibits enzymatic activity on.